How Do Theratechnologies Inc. (NASDAQ:THTX)’s Fundamentals Affect Performance – Fosters Research

How Do Theratechnologies Inc. (NASDAQ:THTX)’s Fundamentals Affect Performance – Fosters Research

Updated: 1 month, 23 days, 2 hours, 43 minutes, 25 seconds ago

The price of Theratechnologies Inc. (NASDAQ:THTX) shares last traded on Wall Street fell -5.04% to $0.92.

Based on available information, 6 analysts follow Theratechnologies Inc. (NASDAQ:THTX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $9.00 and a low of $2.34, we find $3.75. Given the previous closing price of $0.97, this indicates a potential upside of 286.6 percent. THTX stock price is now -29.99% away from the 50-day moving average and -54.59% away from the 200-day moving average. The market capitalization of the company currently stands at $87.34M.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Among analysts, 2 rate the stock a hold while 4 rate it a buy. Brokers who have rated the stock have averaged $4.60 as their price target over the next twelve months.

With the price target of $9, Cantor Fitzgerald recently initiated with Overweight rating for Theratechnologies Inc. (NASDAQ: THTX). On July 29, 2021, Canaccord Genuity Downgraded its previous ‘Buy’ rating to ‘Hold’ on the stock reducing its target price from $8 to quote $3.

Insiders disposed of 20,000 shares of company stock worth roughly $18400.0 over the past 1 year. A total of 0.65% of the company’s stock is owned by insiders.

There have been several recent changes in the stakes of large investors in THTX stock. A new stake in Theratechnologies Inc. shares was purchased by CYNDEO WEALTH PARTNERS, LLC during the first quarter worth $382,000. BELPOINTE ASSET MANAGEMENT LLC invested $40,000 in shares of THTX during the first quarter. In the first quarter, MILLENNIUM MANAGEMENT LLC acquired a new stake in Theratechnologies Inc. valued at approximately $10,000. SIMPLEX TRADING, LLC acquired a new stake in THTX for approximately $1,000. In total, there are 44 active investors with 27.36% ownership of the company’s stock.

A candlestick chart of Theratechnologies Inc. (NASDAQ: THTX) showed a price of $0.9700 on Thursday morning. During the past 12 months, Theratechnologies Inc. has had a low of $0.77 and a high of $3.26. The fifty day moving average price for THTX is $1.2914 and a two-hundred day moving average price translates $2.0143 for the stock.

The latest earnings results from Theratechnologies Inc. (NASDAQ: THTX) was released for Aug, 2022. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.08, beating analysts’ expectations of -$0.12 by 0.04. This compares to -$0.10 EPS in the same period last year. The company reported revenue of $20.81 million for the quarter, compared to $17.85 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 16.58 percent. For the current quarter, analysts expect THTX to generate $22.55M in revenue.

Theratechnologies Inc.(THTX) Company Profile

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.